SCHEMBL215327

SCHEMBL215327

Nc1cccc2c(=O)[nH]ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 15/20 1.00
TDP1 Q9NUW8 2/20 1.00
RECQL P46063 1/20 1.00
ALDH1A1 P00352 4/20 0.60
HSD17B10 Q99714 3/20 0.60
CYP3A4 P08684 2/20 0.60
HPGD P15428 2/20 0.60
KDM4E B2RXH2 1/20 0.60
LMNA P02545 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2C9 P11712 1/20 0.60
RAB9A P51151 1/20 0.60
BLM P54132 1/20 0.60
PARP15 Q460N3 1/20 0.60
TSHR P16473 1/20 0.54
AURKA O14965 1/20 0.54
AURKB Q96GD4 1/20 0.54
INCENP Q9NQS7 1/20 0.54
JAK2 O60674 1/20 0.53
RPS6KA3 P51812 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29519573 1.00 PARP1 (1.00) PARP1TDP1RECQLALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL29519388 0.98 PARP1 (0.96) PARP1TDP1RECQLALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL5496376 0.98 PARP1 (0.96) PARP1TDP1RECQLALDH1A1HSD17B10
SCHEMBL14027180 0.77 PARP1 (0.62) PARP1TDP1RECQLALDH1A1HSD17B10
SCHEMBL307689 0.77 PARP1 (0.62) PARP1TDP1RECQLALDH1A1HSD17B10
SCHEMBL832144 0.75 PARP1 (0.60) PARP1TDP1RECQLALDH1A1HSD17B10
SCHEMBL12463821 0.75 PARP1 (0.60) PARP1TDP1RECQLALDH1A1HSD17B10
SCHEMBL31743106 0.75 PARP1 (0.60) PARP1TDP1RECQLALDH1A1HSD17B10
SCHEMBL2172575 0.75 PARP1 (1.00) PARP1TDP1RECQLALDH1A1HSD17B10
SCHEMBL29492688 0.75 PARP1 (1.00) PARP1TDP1RECQLALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180042919-A1 PARP Inhibitors for the Treatment of Major Depressive Disorder and Related Conditions EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION 2018-02-15 US claimed
US-20120022026-A1 METHOD OF TREATING CANCER ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2012-01-26 US claimed
EP-2387403-A1 METHOD OF TREATING CANCER Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) 2011-11-23 EP claimed
US-20110253692-A1 Electrical heater for vehicle windshields and windows SCHAUBLE RICHARD EGON 2011-10-20 US claimed
WO-2010082821-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO claimed
WO-2010082813-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO claimed
EP-1009404-A4 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS OCTAMER INC (US) 2009-07-01 EP claimed
WO-2001022960-A1 TREATMENT OF CARBON MONOXIDE POISONING CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY DOING BUSINESS AS CAROLINAS MEDICAL CENTER (US) 2001-04-05 WO claimed
EP-1009404-A1 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS Octamer, Inc. (US) 2000-06-21 EP claimed
US-5908861-A Methods for treating inflammation and inflammatory disease using pADPRT inhibitors OCTAMER, INC. (US) 1999-06-01 US claimed
WO-1998051307-A1 METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS OCTAMER, INC. (US) 1998-11-19 WO claimed
WO-1998051308-A1 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS OCTAMER, INC. (US) 1998-11-19 WO claimed
US-20250381221-A1 Compositions and Methods for Treating Cancer IN8BIO INC (US) 2025-12-18 US disclosed
US-20250161247-A1 METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS LANTERN PHARMA INC. (US) 2025-05-22 US disclosed
EP-4554683-A2 METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS Lantern Pharma Inc. (US) 2025-05-21 EP disclosed
US-20240299322-A1 TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES LANTERN PHARMA INC. (US) 2024-09-12 US disclosed
US-5908861-A Methods for treating inflammation and inflammatory disease using pADPRT inhibitors OCTAMER, INC. (US) 1999-06-01 US disclosed
WO-1998051307-A1 METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS OCTAMER, INC. (US) 1998-11-19 WO disclosed
US-5177075-A Antitumor agents WARNER-LAMBERT COMPANY (US) 1993-01-05 US disclosed
EP-0355750-A1 Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process WARNER-LAMBERT COMPANY (US) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161247-A1 METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS PARP1, PARP2, PARP3 PARP1 1/4885TDP1 341/4885RECQL 2523/4885
US-20240299322-A1 TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES PARP1, PARP2, PARP11 PARP1 1/4885TDP1 284/4885RECQL 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.